Imipenem/Cilastatin Kabi

Imipenem, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections in hospitalized patients, including intra‑abdominal, urinary, respiratory and bloodstream infections. GNH USA supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/Cilastatin Kabi is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: provides rapid bacterial eradication in severe abdominal sepsis. Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis. Nosocomial pneumonia: treats hospital‑acquired lung infections caused by Gram‑negative and Gram‑positive bacteria. Skin and soft tissue infections: resolves deep tissue infections resistant to other agents. Septicemia: achieves systemic bacterial clearance in bloodstream infections.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be self‑limited. - Rash: skin erythema or pruritus. - Headache: transient. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Neutropenia or thrombocytopenia: blood cell count reductions. - Acute renal dysfunction: worsening kidney function.

Careful assessment and monitoring are required before and during therapy. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic dysfunction: monitor liver function tests. - History of seizures: use with caution, consider alternative. - Known beta‑lactam allergy: avoid to prevent hypersensitivity. - Pregnancy: safety unknown; prescribe only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potential drug‑drug interactions should be evaluated.

Major Interactions (Avoid): - Valproic acid: reduces anticonvulsant levels, risking breakthrough seizures. - Probenecid: may increase imipenem concentrations, raising toxicity risk. - Concurrent nephrotoxic agents: heighten renal adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function. - Warfarin: observe INR for possible anticoagulation changes.